European Pharmaceutical Review

JANUARY 11, 2024

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. 2017; 6(S1):1–3. Neuropathic pain: The scope of the problem. Pain and Therapy.

Medicine 102

Medicine Pharmacology Management Side effects 102

Pharmaceutical Technology

NOVEMBER 17, 2022

This marks the first update to NICE’s endometriosis guidelines since 2017, representing a huge milestone for patients and practitioners alike. This delay in diagnosis ultimately leads to disease progression and associated complications, such as chronic pelvic pain and infertility, which greatly affects the patients’ quality of life.

Management 102

Management Pharmacology Side effects Patients 102

European Pharmaceutical Review

JUNE 12, 2024

The study included 92 adult patients with confirmed CDI. After treatment, patients were followed up at intervals of 72 hours, three weeks, eight weeks, three months and six months. Safety and quality of life of the patients participating in the study were also assessed. percent of those treated with fidaxomicin.

Safety 111

Safety Patients Side effects Healthcare 111

PM360

OCTOBER 22, 2024

In the pharmaceutical industry, patient support programs (PSPs) and brand teams often work in silos, despite their shared goal of helping patients achieve a certain health outcome. Pharma brands work diligently to win the trust of key stakeholders—namely patients, caregivers, and healthcare providers (HCPs).

Patients 59

Patients Healthcare Provider Pharma Prescription 59

European Pharmaceutical Review

JANUARY 3, 2023

Sensorion, a biotechnology company has announced that the first patient has been enrolled in its NOTOXIS Phase IIa proof of concept clinical trial of SENS-401 (Arazasetron) in cancer patients experiencing cisplatin-induced ototoxicity (permanent hearing loss), a serious side effect of key chemotherapeutic agent cisplatin.

Patients 52

Patients Food and Drug Administration Side effects Food 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Side effects and cost implications.

Side effects 52

Side effects Patients Medical Medicine 52

European Pharmaceutical Review

OCTOBER 19, 2023

These diagnostics have significantly progressed based on rigorous Phase III trial designs and because of the impact these diagnostics have had on patient management. These diagnostics are also paired with therapeutics and act as an imaging biomarker to identify patients who may benefit from the paired therapies.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Side effects Doctors 105

Clarivate

AUGUST 17, 2022

In our latest podcast, Ideas to Innovation, we speak with Dr. Grace Lomax, the clinical director at Patient Connect, part of Clarivate. In 2017, the same year the SDGs came into effect, the United Nations found that less than half of the global population was covered by essential health services. Dr. Grace Lomax.

Healthcare 52

Healthcare Healthcare Patients Physicians 52

Pharmaceutical Technology

JANUARY 27, 2023

However, Briumvi is unlikely to appeal to patients who are already receiving Genentech’s Ocrevus or Novartis’s Kesimpta. Briumvi is the third approved injectable MS treatment directed against CD20 antigen expressed on B cells, with the other therapies being Kesimpta (ofatumumab, approved in 2020) and Ocrevus (ocrelizumab, approved in 2017).

Marketing 52

Marketing Side effects Safety Patients 52

Clarivate

SEPTEMBER 25, 2024

A ‘magic bullet’ medicine that can cure a disease quickly and completely, [1] without deleterious side effects. [2] 3 Patients required many injections over a long time period, and problems also arose from the galenic preparation of arsphenamide, which was insoluble in water.3

Medicine 59

Medicine Side effects Patients Pharmaceutical 59

European Pharmaceutical Review

JANUARY 25, 2024

Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. They detail the medication’s intended use, proper administration, potential side effects and precautions. percent as EU average with some Member States as high as 25 percent).

Healthcare 98

Healthcare Healthcare Safety Electronics 98

European Pharmaceutical Review

AUGUST 24, 2022

The ultimate goal of the ADC concept is to maximise the potency of treatment and reduce unwanted side effects on healthy tissues. Consequently the market dynamics were slow, with just three approved ADC drugs until 2017. The culmination of two decades of learning.

Engineering 104

Engineering Side effects Marketing Patients 104

pharmaphorum

JANUARY 3, 2023

” Rawlins was knighted in the 1999 Queen’s New Year Honours for services to the improvement of patient protection from the side effects of medicines, and in 2017 was appointed Knight Grand Cross of the Order of the British Empire (GBE) for services to the safety of medicines, healthcare, and innovation.

Side effects 52

Side effects Medicine Safety Healthcare 52

Pharmaceutical Technology

APRIL 24, 2023

The British institute that oversees a therapy’s cost-effectiveness opted for the recommendation based on clinical data from the Phase II CAPTIVATE and the Phase III GLOW studies. The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

pharmaphorum

SEPTEMBER 11, 2022

All told, 7% of patients treated with SpringWorks’ therapy had a complete response to treatment, and 95% of side effects liked to the drug were mild (grade 1 or 2), most commonly diarrhoea, rash, and elevated levels of phosphate in the blood.

Side effects 52

Side effects Leads Safety Patients 52

pharmaphorum

JULY 11, 2022

The company had been eyeing a possible regulatory filing for fitusiran this year, but has now set back the timeline – possibly until 2024 – while it gathers data on the revised dosing schedule, in the hope of maintaining efficacy with fewer clotting side effects.

Engineering 52

Engineering Side effects Competition Sales 52

Pharmaceutical Technology

AUGUST 12, 2022

Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. These cells can be taken originally from the patient or another individual. However, the relapsed/refractory (R/R) rate for patients can be up to 50%.

Side effects 52

Side effects Marketing Engineering Patients 52

pharmaphorum

JULY 26, 2022

Other late-stage trials on the go include BROOKLYN, which is enrolling adults with HeFH whose LDL cholesterol is not adequately controlled despite being on maximally tolerated lipid-modifying therapies, and a cardiovascular outcomes study in ASCVD patients called PREVAIL. So why will obicetrapib avoid the pitfalls of its predecessors?

Side effects 52

Side effects Safety Pharma Patients 52

European Pharmaceutical Review

AUGUST 15, 2024

BTKis, oral drugs given as continuous monotherapy, have revolutionised the treatment of CLL, with the first generation BTKi ibrutinib receiving European Medicines Agency (EMA) approval in 2014; however, side-effects (such as cardiovascular toxicities 2 ) have limited its suitability. for all-comers; HR=0.52

Safety 52

Safety Patients Medical Medicine 52

pharmaphorum

SEPTEMBER 14, 2022

After years of stagnation in the treatment of neurodegenerative disorder amyotrophic lateral sclerosis (ALS), patients in the US could soon have two new treatment options – but their pricing is already raising red flags.

Side effects 64

Side effects FDA Medical Patients 64

pharmaphorum

JUNE 28, 2022

aureus bloodstream infections in the US, according to 2017 data from the Centers for Disease Control and Prevention (CDC). The ERADICATE study enrolled 390 patients with complicated SAB, including some with endocarditis, and met the objective of showing non-inferiority of ceftobiprole versus daptomycin given with or without aztreonam.

Side effects 52

Side effects FDA Marketing Government 52

Pharmaceutical Technology

NOVEMBER 30, 2022

A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The same can be said for the US. of adults were overweight, 42.4%

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The same can be said for the US. of adults were overweight, 42.4%

Medical 98

Medical Manufacturing Insurance Side effects 98

World of DTC Marketing

FEBRUARY 23, 2021

How long do you believe it will be before the media once again runs stories about drug prices or drug side effects? The increase followed total Humira price hikes of 19 percent during 2017 and 2018, according to a survey by the nonprofit Institute for Clinical and Economic Review, which deemed the increases unjustified.

Pharma 164

Pharma Side effects Media Insurance 164